Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | PAM | P19021 | 2/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CTH | P32929 | 1/20 | 0.36 |
| ▸ | CBS | P35520 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172609 | 1.00 | EPHX2 (0.41) | EPHX2CES2HSD17B10BLMPMP22 | |
| SCHEMBL15010748 | 1.00 | EPHX2 (0.41) | EPHX2CES2HSD17B10BLMPMP22 | |
| SCHEMBL25696126 | 1.00 | EPHX2 (0.41) | EPHX2CES2HSD17B10BLMPMP22 | |
| SCHEMBL1674638 | 1.00 | EPHX2 (0.41) | EPHX2CES2HSD17B10BLMPMP22 | |
| SCHEMBL12703479 | 1.00 | EPHX2 (0.41) | EPHX2CES2HSD17B10BLMPMP22 | |
| SCHEMBL295696 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL10339700 | 0.92 | — | — | |
| SCHEMBL28636215 | 0.92 | — | — | |
| SCHEMBL24207928 | 0.91 | CES2 (0.53) | EPHX2CES2PAMTSHRTHRB | |
| SCHEMBL17947537 | 0.91 | CES2 (0.47) | EPHX2CES2PAMPTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0524225-A1 | METHOD FOR PREPARING PERFLUOROPOLYETHERS. | DU PONT (US) | 1993-01-27 | — | — | EP | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024263781-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-117715904-A | CDK2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2022236058-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20170008904-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2017-01-12 | — | — | US | disclosed |
| EP-1886759-B1 | WATER-SOLUBLE PREFLUX AND USE THEREOF | SHIKOKU CHEM (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-7754105-B2 | Water-soluble preflux and usage of the same | SHIKOKU CHEMICALS CORPORATION (JP) | 2010-07-13 | — | — | US | disclosed |
| US-7576071-B2 | Antithrombotic compound | SANOFI-AVENTIS (FR) | 2009-08-18 | — | — | US | disclosed |
| US-20080318070-A1 | Water-Soluble Preflux and Usage of the Same | SHIKOKU CHEMICALS CORPORATION (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1886759-A1 | WATER-SOLUBLE PREFLUX AND USE THEREOF | SHIKOKU CHEMICALS CORPORATION (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-20070293442-A1 | ANTITHROMBOTIC COMPOUND | SANOFI-AVENTIS (FR) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008904-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, XIAP, TP53 | EPHX2 3245/4885CES2 4257/4885HSD17B10 3330/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EPHX2 1890/4885CES2 1669/4885HSD17B10 2107/4885 |
| US-20070293442-A1 | ANTITHROMBOTIC COMPOUND | F13B, SERPINC1, SELP | EPHX2 717/4885CES2 2485/4885HSD17B10 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.